Abstract | BACKGROUND: METHOD: Subjects with DSM-IV-defined OCD for > or =3 years who had failed > or =2 adequate SRI trials and had a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of > or =20 were recruited. Current medications were continued. Subjects were randomly assigned to random-order, 2-week blocks of once-weekly morphine, lorazepam, and placebo. Week 2 dosage was increased, decreased, or maintained depending on response and side effects. RESULTS: We enrolled 23 subjects, who had failed 2 to 6 SRI trials. The median screening Y-BOCS score was 29. The median Y-BOCS score after morphine (highest dose) was 25 (median decrease = 13%). Seven subjects (30%) were responders (Y-BOCS decreases > or =25%). The median Y-BOCS score after lorazepam (highest dose) was 27 (median decrease = 6%). Four subjects (17%) responded to lorazepam; 1 was a morphine responder. The median Y-BOCS score after placebo (highest dose) was 27 (median decrease = 7%), and no subject responded. Responses differed significantly among the 3 conditions (Friedman 2-way analysis of variance, chir(2) = 13.92, df = 2, p = .01). Wilcoxon matched-pairs signed-rank tests (T = 56.5, p = .05) showed significance for morphine versus placebo but not lorazepam versus placebo. CONCLUSION: Our results support the hypothesis that once-weekly oral morphine can reduce symptoms in some treatment-resistant OCD patients. The mechanism of action is unknown. Further studies of mu-agonists and glutamate antagonists are warranted.
|
Authors | Lorrin M Koran, Elias Aboujaoude, Kim D Bullock, Bettina Franz, Nona Gamel, Michael Elliott |
Journal | The Journal of clinical psychiatry
(J Clin Psychiatry)
Vol. 66
Issue 3
Pg. 353-9
(Mar 2005)
ISSN: 0160-6689 [Print] United States |
PMID | 15766302
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Narcotics
- Placebos
- Receptors, Opioid, mu
- Serotonin Uptake Inhibitors
- Morphine
- Lorazepam
|
Topics |
- Administration, Oral
- Adult
- Double-Blind Method
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- Humans
- Lorazepam
(therapeutic use)
- Male
- Morphine
(administration & dosage, pharmacology, therapeutic use)
- Narcotics
(administration & dosage, pharmacology, therapeutic use)
- Obsessive-Compulsive Disorder
(diagnosis, drug therapy, psychology)
- Placebos
- Psychiatric Status Rating Scales
- Receptors, Opioid, mu
(agonists, drug effects)
- Selective Serotonin Reuptake Inhibitors
(therapeutic use)
- Treatment Outcome
|